Aron Mosnaim

Aron David Mosnaim is a neuroscientist, researcher, and academic. He is a professor of Cellular and Molecular Pharmacology and an adjunct professor of Psychiatry and Behavioral Sciences in the Chicago Medical School at Rosalind Franklin University of Medicine and Science.[1]

Aron David Mosnaim
Occupation(s)Neuroscientist, researcher, and academic
Academic background
EducationPharmD degree
PhD in Organic Chemistry
Alma materUniversity of Chile
University of Strathclyde
Academic work
InstitutionsRosalind Franklin University of Medicine and Science
International Neuropsychiatry Consultants

Mosnaim is most known for his research covering the areas of basic and clinical neuro- and immunopharmacology of biogenic amines and opioid peptides in neuropsychiatric conditions, including depression, headache pain, as well as movement and posttraumatic stress disorders.[2] He has co-edited four scientific books on Noncatecholic Phenylethylamines (2 volumes),[3] Posttraumatic Stress Disorder,[4] and Tardive Dyskinesia.[5]

Mosnaim has served as a Consultant to the Pan American Health Organization (1982–1985), Member of the United States Pharmacopeia Convention (1990 and 1995), and Director of International Neuropsychiatry Consultants (1987–2020). Additionally, he is a Fellow of The Chemical Society (1977) and a Senior Fellow of the American Institute of Therapeutics (2019).[1]

Early life and education

Mosnaim earned a Doctor of Pharmaceutical Sciences degree from the University of Chile (1964) and joined the Faculty of the university's School of Medicine. He was awarded a PhD degree in Organic Chemistry from Glasgow’s Strathclyde University (1969). After a brief tenure at the University of Chicago, he received a postdoctoral fellowship at Northwestern University (1970).[2]

Career

In 1971, Mosnaim joined the University of Health Sciences/The Chicago Medical School as an assistant professor in the Department of Pharmacology. He was promoted to Associate Professor and Acting Chairman (1974), and to a Full Professorship in 1979. He has been serving as a professor of Cellular and Molecular Pharmacology and adjunct professor of Psychiatry and Behavioral Sciences at The Chicago Medical School/Rosalind Franklin University.[1]

Mosnaim holds an Honorary Full Professorship at the University of Chile College of Pharmaceutical Sciences.

Research

Mosnaim has published over 150 papers in peer-reviewed Journals, more than 20 invited reviews and book chapters, and presented research in more than 200 scientific meetings.[2]

Early in his research career (1967), Mosnaim contributed to elucidate the metabolic pathway of the then widely used toxic insecticide DDT (dichlorodiphenyltrichloroethane), and in a series of publications (1969–1972) helped to understand the mechanism of halogenation by cupric salts of carcinogenic anthracene and pyrene compounds.[6] His laboratory demonstrated the presence of phenylethylamine, commonly viewed as the endogenous amphetamine, in mammalian tissues, and his work elucidated this amine’s in vivo and in vitro brain metabolic pathway.[7][8][9] His work, animal models, contributed to establish phenylethylamine brain levels as a biological marker for various neuropsychiatric disorders, and to evaluate its brain changes in response to different classes of psychotropic drugs.[10][11] Further research identified some of the physiological functions, and described relevant behavior and toxicological effects of phenylethylamine and various structurally related trace amines.[12][13]

Mosnaim reported plasma levels of the endogenous opioid pentapeptide methionine-enkephalin in various patient populations, and the effect of selected classes of drugs on its degradation kinetics,[14] suggesting that its significant increase in chronic cluster and migraine patients during an acute headache episode could serve as a biological marker for these illnesses.[15][16] He also clarified reports of the activity of platelet monoamine oxidase and the role of dietary phenylethylamine and tyramine in the etiology of migraine headaches.[17]

Mosnaim contributed to document the association of tardive dyskinesia and drug-induced parkinsonism, and in identifying sub-types, cognitive deficits, and some of the risk factors associated with increased vulnerability to this condition.[18][19][20][21] He participated in studies finding comorbidity of pain, dermatological and allergic conditions, as well as decreased natural killer cell activity, in posttraumatic stress disorder patients.[22] He reported the decrease of this immune function in septic shock and human immunodeficiency virus-1 positive individuals, as well as its significant increase by various substances with widely different chemical structures and biological activities, e.g., enkephalins, α-interferon, interleukin-2, taxol, and lipopolysaccharide.[23][24][25]

Bibliography

Selected edited books
  • Noncatecholic phenylethylamines Part 1 (1978) ISBN 0-8247-6616-4
  • Noncatecholic phenylethylamines Part 2 (1980) ISBN 0-8247-6721-7
  • Tardive Dyskinesia: Biological Mechanisms & Clinical Aspects (1989) ISBN O-8804-8176-5
  • Posttraumatic Stress Disorder: Etiology, Phenomenology, and Treatment (1990) ISBN 0-8804-8299-0

Selected articles
  • Inwang, E. E., Mosnaim, A. D., & Sabelli, H. C. (1973). Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. Journal of Neurochemistry, 20(5), 1469–1473.
  • Sabelli, H. C., & MOSNAIM, A. D. (1974). Phenylethylamine hypothesis of affective behavior. American Journal of Psychiatry, 131(6), 695–699.
  • Wolf, M. E., & Mosnaim, A. D. (1983). Phenylethylamine in neuropsychiatric disorders. General Pharmacology: The Vascular System, 14(4), 385–390.
  • Wolf, M. E., Alavi, A., & Mosnaim, A. D. (1988). Posttraumatic stress disorder in Vietnam veterans—clinical and EEG findings: Possible therapeutic effects of carbamazepine. Biological Psychiatry.
  • Mosnaim, A. D., Ranade, V. V., Wolf, M. E., Puente, J., & Valenzuela, M. A. (2006). Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents. American journal of therapeutics, 13(3), 261–273.

References
  1. "Aron D. Mosnaim, PhD". Rosalind Franklin University.
  2. "walsh medical media | journals | open access journals". www.walshmedicalmedia.com. November 25, 2019.
  3. "Noncatecholic phenylethylamines".
  4. Kinzie, J. David (October 7, 1991). "Posttraumatic stress disorder: Etiology, phenomenology and treatment. By M. E. Wolf, and A. D. Mosnaim, editors. Washington, D.C.: American Psychiatric Press, Inc., 1990, 270 pages". Journal of Traumatic Stress. 4 (4): 607–608. doi:10.1002/jts.2490040416 – via CrossRef.
  5. "Tardive dyskinesia : biological mechanisms and clinical aspects".
  6. Mosnaim, A. D.; Wolf, M. E.; Saavedra, I.; Amaro, A. M.; Cordano, G.; Nonhebel, D. C. (January 1, 1973). "Reaction of cupric(ii) halides with organic compounds-VIII pyrene and some 3-substituted pyrenes". Tetrahedron Letters. 14 (17): 1491–1494. doi:10.1016/S0040-4039(01)95980-5 – via ScienceDirect.
  7. Mosnaim, A. D.; Inwang, E. E.; Sugerman, J. H.; DeMartini, W. J.; Sabelli, H. C. (June 7, 1973). "Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression". Biological Psychiatry. 6 (3): 235–257. PMID 4732254 – via PubMed.
  8. Inwang, E. E.; Mosnaim, A. D.; Sabelli, H. C. (May 7, 1973). "Isolation and characterization of phenylethylamine and phenylethanolamine from human brain". Journal of Neurochemistry. 20 (5): 1469–1473. doi:10.1111/j.1471-4159.1973.tb00259.x. PMID 4716838. S2CID 8349615 – via CrossRef.
  9. "Noncatecholic phenylethylamines. Pt. 1 Phenylethylamine: biological mechanisms and clinical aspects ; Mosnaim, Aron D., Wolf, Marion E".
  10. Wolf, Marion E.; Mosnaim, A. D. (January 1, 1983). "Phenylethylamine in neuropsychiatric disorders". General Pharmacology: The Vascular System. 14 (4): 385–390. doi:10.1016/0306-3623(83)90020-4. PMID 6352395 – via ScienceDirect.
  11. Sabelli, H. C.; Vazquez, A. J.; Mosnaim, A. D.; Madrid-Pedemonte, L. (March 7, 1974). "2-Phenylethylamine as a possible mediator for Δ9-tetrahydrocannabinol-induced stimulation". Nature. 248 (5444): 144–145. Bibcode:1974Natur.248..144S. doi:10.1038/248144a0. PMID 4274244. S2CID 4168572 – via www.nature.com.
  12. Mosnaim, Aron D.; Callaghan, Owen H.; Hudzik, Thomas; Wolf, Marion E. (April 1, 2013). "Rat Brain-Uptake Index for Phenylethylamine and Various Monomethylated Derivatives". Neurochemical Research. 38 (4): 842–846. doi:10.1007/s11064-013-0988-1. PMID 23389662. S2CID 254860661 – via Springer Link.
  13. Mosnaim, Aron D.; Wolf, Marion E.; III. O’Donnell, James J.; Hudzik, Thomas (July 3, 2020). "β-Phenylethylamine and various monomethylated and para-halogenated analogs. Acute toxicity studies in mice". Drug and Chemical Toxicology. 43 (4): 369–372. doi:10.1080/01480545.2018.1551899. PMID 30614291. S2CID 58557529 – via CrossRef.
  14. Mosnaim, Aron D.; Puente, Javier; Saavedra, Rolando; Diamond, Seymour; Wolf, Marion E. (December 4, 2002). "In vitro Human Plasma Leucine5-Enkephalin Degradation Is Inhibited by a Select Number of Drugs with the Phenothiazine Molecule in Their Chemical Structure". Pharmacology. 67 (1): 6–13. doi:10.1159/000066781. PMID 12444298. S2CID 22740728 – via Silverchair.
  15. Mosnaim, Aron D.; Wolf, Marion E.; Chevesich, Jorge; Callaghan, Owen H.; Diamond, Seymour (July 7, 1985). "Plasma Methionine Enkephalin Levels – A Biological Marker for Migraine?". Headache: The Journal of Head and Face Pain. 25 (5): 259–267. doi:10.1111/j.1526-4610.1985.hed2505259.x. PMID 4030316. S2CID 35728043 – via CrossRef.
  16. Mosnaim, Aron D.; Diamond, Seymour; Freitag, Frederick; Chevesich, Jorge; Wolf, Marion E.; Solomon, Glen (June 7, 1987). "Plasma and Platelet Methionine-Enkephalin Levels in Chronic Cluster Patients During an Acute Headache Episode". Headache: The Journal of Head and Face Pain. 27 (6): 325–328. doi:10.1111/j.1526-4610.1987.hed2706325.x. PMID 3654188. S2CID 29924147 – via CrossRef.
  17. "Migraine and the contents of tyramine and phenylethylamine in food – Biological Psychiatry".
  18. Wolf, M E; Chevesich, J; Lehrer, E; Mosnaim, A D (October 1, 1983). "The clinical association of tardive dyskinesia and drug-induced parkinsonism". Biological Psychiatry. 18 (10): 1181–1188. PMID 6140032 – via Europe PMC.
  19. Wolf, Marion E.; Mosnaim, Aron D. (August 7, 1984). "Identifying Subtypes of Tardive Dyskinesia". Psychiatric Services. 35 (8): 828–830. doi:10.1176/ps.35.8.828. PMID 6479919 – via CrossRef.
  20. Wolf, Marion E.; Ryan, Joseph J.; Mosnaim, Aron D. (August 7, 1983). "Cognitive functions in tardive dyskinesia". Psychological Medicine. 13 (3): 671–674. doi:10.1017/S0033291700048108. PMID 6137851. S2CID 26957713 – via Cambridge University Press.
  21. Wolf, M. E.; DeWolfe, A. S.; Ryan, J. J.; Lips, O.; Mosnaim, A. D. (September 1, 1985). "Vulnerability to tardive dyskinesia". The Journal of Clinical Psychiatry. 46 (9): 367–368. PMID 2863257 – via Europe PMC.
  22. "Pain, dermatological and allergic conditions in post traumatic stress disorder".
  23. Maturana, Patricio; Puente, Javier; Miranda, Dante; Sepulveda, Cecilia; Wolf, Marion E.; Mosnaim, Aron D. (March 1, 1991). "Natural killer cell activity in patients with septic shock". Journal of Critical Care. 6 (1): 42–45. doi:10.1016/0883-9441(91)90032-O – via ScienceDirect.
  24. Sepúlveda, Cecilia; Puente, Javier; Weinstein, Caroline; Wolf, Marion E.; Mosnaim, Aron D. (November 7, 1997). "ENHANCEMENT OF NATURAL KILLER CELL ACTIVITY IN HIV-1-INFECTED SUBJECTS BY A MIXTURE OF THE CALCIUM IONOPHORE A23187 AND THE PHORBOL ESTER TPA: LACK OF RESPONSE TO A SIMILAR CHALLENGE WITH INTERLEUKIN-2 OR α-INTERFERON". American Journal of Therapeutics. 4 (11): 413–421. doi:10.1097/00045391-199711000-00013. PMID 10423640. S2CID 42963577 – via journals.lww.com.
  25. Puente, J.; Carvajal, T.; Parra, S.; Miranda, D.; Sepulveda, C.; Wolf, M. E.; Mosnaim, A. D. (June 7, 1993). "In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with alpha-interferon and interleukin-2". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 31 (6): 271–275. PMID 8335423 – via PubMed.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.